Disease-modifying therapy in MS: A critical review of the literature. Part II: Assessing efficacy and dose-response

Journal of Neurology, Supplement

Volumn 251, Issue 5, 2004, Pages

  Goodin, Douglas S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Disease modifying therapy; Dose response; Efficacy; Evidence based medicine; Multiple sclerosis

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE;

CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL;

BIOLOGICAL RESPONSE MODIFIERS; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; HUMANS; MULTIPLE SCLEROSIS; REVIEW LITERATURE; TREATMENT OUTCOME;

EID: 5644221510     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-004-1508-7     Document Type: Conference Paper

References (30)

1. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S, the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines (2002) Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58:169-178
2. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW and the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2003) The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 61:1332-1338
3. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
4. Paty DW, Li DKB, the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in remitting and relapsing multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:662-667
5. The IFNB Multiple Sclerosis Study Group and the UBC MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology 45:1277-1285
6. rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al. and the Multiple Sclerosis Collaborative Research Group (MSCRG) (1996) Intramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. Ann Neurol 39:285-294
7. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Alam JJ, Fischer JS, Goodkin DE, Granger CV, Lajaunie M, Martens-Davidson AL, Meyer M, Sheeder J, Choi K, Scherzinger AL, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Whitham RH, et al. (1998) Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 43:79-87
8. PRISMS Study Group (1998) Randomized double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis. Lancet 352:1498-1504
9. European Study Group on Interferon beta-1b in Secondary Progressive MS (1998) Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491-1497
10. Li DK, Paty DW, UBC MS/MRI Analysis Research Group and the PRISMS Study Group (1999) Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta 1a Subcutaneously in Multiple Sclerosis. Ann Neurol 46:197-206
11. nd Annual Meeting of the American Academy of Neurology, San Diego, California, 29 April-6 May (Abstract LBN, 002)
12. SPECTRIMS Study Group (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 56:1496-1504
13. PRISMS Study Group (2001) PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56:1628-1636
14. Li DKB, Zhao GJ, Paty DW, the University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 56:1505-1513
15. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN and the IMPACT Investigators (2002) Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology 59:679-687
16. Williams GJ, Witt PL (1998) Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and Avonex. J Interferon Cytokine Res 18:967-975
17. Stürzebecher S, Maibauer R, Heuner A, Beckmann K, Aufdembrincke B (1999) Pharmacodynamic comparison of single doses of IFN-β1a and IFN-β1b in healthy volunteers. J Interferon Cytokine Res 19:1257-1264
18. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS and the Copolymer Multiple Sclerosis Study Group (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45:1268-1276
19. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS and the Copolymer Multiple Sclerosis Study Group (1998) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 50:701-708
20. Comi G, Filippi M, Wolinsky JS (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 49:290-297
21. Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP, Myers LW, Panitch HS, Pruitt A, Rose JW, Kachuck N, Wolinsky JS and the Copolymer 1 Multiple Sclerosis Study Group (2000) Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 6:255-266
22. Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP (2001) A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFN beta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur J Neurol 8:141-148
23. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, Brochet B, Berry I, Rolland Y, Froment JC, Cabanis E, Iba-Zizen MT, Gandon JM, Lai HM, Moseley I, Sabouraud O (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112-118
24. Millefiorini E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M, Morino S, Morra VB, Bozzao A, Calo' A, Bernini ML, Gambi D, Prencipe M (1997) Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 244:153-159
25. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T and the Mitoxantrone in Multiple Sclerosis Study Group (MIMS) (2002) Mitoxantrone in progressive multiple sclerosis (MS): a placebo-controlled, double-blind, randomised multicenter study. Lancet 360:2018-2025
26. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M and the Independent Comparison of Interferon (INCOMIN) Trial Study Group (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359:1453-1460
27. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B, the EVIDENCE Study Group and the UBC MS/MRI Research Group (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 59:1496-1506
28. th Annual Meeting of the Consortium for Multiple Sclerosis Centers, San Diego, California, USA, 28 May-1 June, P25
29. Goodin DS (2004) Disease-modifying therapy in MS: A critical review of the literature. Part I: Analysis of clinical trial errors. J Neurol (in press)
30. Goodin DS (2001) Interferon-β therapy in multiple sclerosis: evidence for a clinically relevant dose response. Drugs 61:1693-1703